These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23235192)
41. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas]. Banzo J; Abós MD; Prats E; García F; Razola P Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088 [No Abstract] [Full Text] [Related]
42. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Gauthé M; Richard-Molard M; Cacheux W; Michel P; Jouve JL; Mitry E; Alberini JL; Lièvre A; Dig Liver Dis; 2015 Jun; 47(6):443-54. PubMed ID: 25766918 [TBL] [Abstract][Full Text] [Related]
43. Standard imaging techniques for neuroendocrine tumors. Bushnell DL; Baum RP Endocrinol Metab Clin North Am; 2011 Mar; 40(1):153-62, ix. PubMed ID: 21349416 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography. Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080 [TBL] [Abstract][Full Text] [Related]
45. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours. Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750 [TBL] [Abstract][Full Text] [Related]
46. Molecular imaging for neuroendocrine tumours. Antwi K; Nicolas G; Wild D; Christ E Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831 [TBL] [Abstract][Full Text] [Related]
48. [Detection of a neuroendocrine differentiated cystic pancreatic lesion by gallium-68-DOTATOC-PET/CT with inconclusive MRI, CT and ultrasound diagnosis]. Fröling V; Denecke T; Pöllinger A; Schreiter NF Rofo; 2010 Feb; 182(2):175-7. PubMed ID: 19998214 [No Abstract] [Full Text] [Related]
49. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
50. Peptide imaging with somatostatin analogues: more than cancer probes. Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033 [TBL] [Abstract][Full Text] [Related]
51. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185 [TBL] [Abstract][Full Text] [Related]
52. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors. Bal CS; Gupta SK; Zaknun JJ Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981 [TBL] [Abstract][Full Text] [Related]
53. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539 [TBL] [Abstract][Full Text] [Related]
54. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. Panagiotidis E; Bomanji J PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933 [TBL] [Abstract][Full Text] [Related]
55. Rare case of gall bladder neuroendocrine tumor: ¹⁸F-FDG and ⁶⁸Ga-DOTANOC PET/CT findings. Chakraborty PS; Dhull VS; Karunanithi S; Roy SG; Kumar R Rev Esp Med Nucl Imagen Mol; 2014; 33(5):316-7. PubMed ID: 25043774 [No Abstract] [Full Text] [Related]
57. Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with ⁶⁸Ga-labelled somatostatin analogues: could this be tailored according to specific clinical context and individual patient requirement? Basu S Nucl Med Commun; 2012 Oct; 33(10):1007-10. PubMed ID: 22850607 [No Abstract] [Full Text] [Related]
58. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Rufini V; Baum RP; Castaldi P; Treglia G; De Gaetano AM; Carreras C; Kaemmerer D; Hommann M; Hörsch D; Bonomo L; Giordano A Abdom Imaging; 2012 Dec; 37(6):1004-20. PubMed ID: 22422069 [TBL] [Abstract][Full Text] [Related]
59. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986 [TBL] [Abstract][Full Text] [Related]
60. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]